In recent years, a substantial body of evidence has emerged to support the use of lipid-lowering therapy in the prevention of coronary artery disease, and many physician groups have endors the management of dyslipidemia in at-risk patients.
An important consideration in such endorsements has been the issue of the safety of lipid intervention ; many early primary-and secondary-prevention studies reported either no reduction in all-cause mortality rates or an increase in non-coronary artery disease mortality rates in treated patients. ese observations raised serious concerns about the safety of such therapy.
However, 2 landmark studies, the Scandinavian Simvastatin Survival Study (4S) and the West of Scotland Coronary Prevention Study (WOSCOPS), have contributed greatly to alleviating these concerns.
In this article, a review of the epidemiologic evidence supporting the use of lipid modification will be presented, including important trials and meta-analyses, and the cost-effectiveness of lipid-modifying treatment will be discussed.
Mots-clés Pascal : Hypolipémiant, Traitement, Chimiothérapie, Cardiopathie coronaire, Prévention, Efficacité traitement, Dyslipémie, Facteur risque, Homme, Revue bibliographique, Coût, Economie santé, Epidémiologie, Lipide, Appareil circulatoire pathologie, Métabolisme pathologie
Mots-clés Pascal anglais : Antilipemic agent, Treatment, Chemotherapy, Coronary heart disease, Prevention, Treatment efficiency, Dyslipemia, Risk factor, Human, Bibliographic review, Costs, Health economy, Epidemiology, Lipids, Cardiovascular disease, Metabolic diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0076208
Code Inist : 002B02N. Création : 31/05/1999.